Michael Malecki

Michael specialises in US Market Access and Pricing Strategy. His expertise in navigating the complex US payer landscape is well recognized and his analytical acumen is rooted in an in-depth understanding of principal-agent dynamics in healthcare, a focus sharpened during his tenure at Decision Resources Group.

Michael holds a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School and has worked in various leadership roles in industry, including leading the commercial strategy at Blue Note Therapeutics and significant roles within Amgen’s Value & Access and Regulatory Policy teams.